KalVista Pharmaceuticals Inc. (NASDAQ: KALV) announced interim results from its KONFIDENT-KID clinical trial evaluating EKTERLY (sebetralstat) for treating hereditary angioedema ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE